Immuno-Biological Laboratories Co., Ltd. (4570) Stock Price

Immunobiological Research Institute operates two primary business segments: antibody-related business and cosmetics-related business. The antibody-related business provides diagnostic reagent services, testing services, and TG silkworm services. The diagnostic reagent service manufactures and sells research reagents based on antibodies and in vitro diagnostic pharmaceuticals, while also offering contract services related to reagents.

The testing service provides detailed lipoprotein profiling analysis services centered on LipoSEARCH®. These services are utilized in clinical research, basic research, animal healthcare, and private medical practice. The company has also established the IBL Analysis Center, which conducts contract testing using proprietary ELISA measurement kits for research purposes.

The TG silkworm service provides technology to mass-produce target proteins and antibodies using silkworm cocoons. Using this technology, the company also manufactures and sells human-type collagen. Additionally, the cosmetics-related business develops and sells cosmetic products containing Neo Silk®—human-type collagen type I.

Through these business operations, Immunobiological Research Institute aims to contribute to the medical and beauty sectors. In particular, the antibody-related business supports research institutions and pharmaceutical companies through the sale of research reagents and contract services. The cosmetics-related business provides safe, innovative cosmetic raw materials and develops products that consumers can use with confidence.

Immunobiological Research Institute is advancing a growth strategy based on antibody technology. The company aims to make a full-scale entry into the diagnostic pharmaceutical market and expand its research reagent market presence overseas. Additionally, by streamlining development costs for pharmaceutical candidates through selective focus and concentration, and by improving profitability of underperforming businesses, the company seeks to expand revenues and stabilize its financial position.

As a medium to long-term management strategy, Immunobiological Research Institute is focusing on antibody-related businesses. In particular, for diagnostic reagent services, the company is strengthening digital marketing and building information strategies utilizing social media. Through these efforts, the company aims to promote its proprietary technology globally and expand sales. The company is also focusing on commercializing in vitro diagnostic pharmaceuticals to achieve stable revenues.

The company is making priority investments in research and development to enrich its pipeline of therapeutic and diagnostic pharmaceuticals. It is concentrating resource allocation and improving research and development efficiency while advancing recruitment of talented personnel. The company is also actively identifying useful seeds held by overseas companies.

Furthermore, Immunobiological Research Institute is advancing mutual utilization of diagnostic drug development technology through a business partnership with Sysmex Corporation. Through this collaboration, the company aims to develop innovative, high-quality products and provide them to the global market. The company is optimizing its antibody library and expanding its diagnostic pharmaceutical market business.